What is Healthcare Investment Banking and Venture Capital? Healthcare Investment Banking refers to a group that solely focuses on healthcare companies and has sufficient capabilities to advise clients on strategic transactions such as Mergers & Acquisitions, and divestitures, and capital services including debt, equity, etc.
Amazon Web Services tapped 10 startups as finalists to participate in its 2022 healthcare accelerator focused on health equity, it announced Wednesday.
A financial services professional has pleaded guilty to insider trading of shares in a clinical stage biotech.
The Coalition for Epidemic Preparedness Innovations will provide funding up to $375,000 to support the development of laboratory tools to assess monkeypox vaccines.
Financial analysis of Elevance Health, formerly known as Anthem, and the rising revenues for the quarter, which is attributed to increased enrollment.
There are signs that rising inflation could impact biotech’s outlook into the second half of the year.
Tebra clinched $72 million in new funding to scale up its all-in-one digital platform that supports medical practices and drive investment in R&D.
Over the last 15 years, Third Rock Ventures has raised $3.8B, with its most recent fund bringing in $1.1B. Third Rock plans to create 10 new biotech firms and to invest in other players.
Dren Bio closes its series B financing round with $65M in new support from Pfizer, bringing Dren’s total capital is $156M. This is the most recent instance of Pfizer investing in emerging biotechs and science firms.
Oracle has closed its $28.3 billion acquisition of electronic health record company Cerner.
Healthcare spending could decrease by more than $11B in 2023 if enhanced premium tax credits enacted in the American Rescue Plan expire. Hospital spending would decline by nearly $3.8B, spending on physician practices would drop $1.3B, and prescription drug spending would drop $3.4B, research finds.
Kentucky-based payer Humana has decided to sell its 60% stake in Kindred at Home’s hospice business to PE firm Clayton, Dubilier & Rice for $2.8 billion. As Humana has branched into the home health sector, the decision to sell their stake is one that company planned to do following the following the investment. Humana will still maintain a minority ownership position with Kindred at Home.
After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%.
